|
07 Dec 2009 |
Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy
|
|
07 Dec 2009 |
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
|
|
07 Dec 2009 |
Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
|
|
07 Dec 2009 |
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
|
|
07 Dec 2009 |
Immunomedics Announces Preclinical Results of Milatuzumab in B-Cell Malignancies
|
|
04 Dec 2009 |
Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
|
|
04 Dec 2009 |
Biotest AG: European Commission grants approval of Zutectra(R)
|
|
03 Dec 2009 |
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
|
|
03 Dec 2009 |
Kyto Biopharma Inc. Announces High-Affinity Monoclonal Antibody to the Cellular Receptor for Transcobalamin (Vitamin B12)
|
|
02 Dec 2009 |
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
|
|
01 Dec 2009 |
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
|
|
01 Dec 2009 |
Trellis Bioscience Grants MedImmune License for Its Anti-RSV Antibodies
|
|
30 Nov 2009 |
Xencor Licenses Antibody Optimization Technology
|
|
24 Nov 2009 |
Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
|
|
23 Nov 2009 |
Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
|
|
23 Nov 2009 |
GLYCOTOPE receives regulatory approval for GlycoExpress Technology and initiates first clinical trial with lead antibody GT-MAB 2.5 GEX
|
|
20 Nov 2009 |
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
|
|
20 Nov 2009 |
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology
|
|
19 Nov 2009 |
Merck KGaA: CHMP Opinion for Erbitux in Advanced Non-Small Cell Lung Cancer
|
|
18 Nov 2009 |
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
|
|
18 Nov 2009 |
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
|
|
17 Nov 2009 |
Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
|
|
17 Nov 2009 |
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
|
|
17 Nov 2009 |
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB BIOLOGICS LICENSE APPLICATION
|
|
17 Nov 2009 |
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
|
